Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians.

Bodei L, Chiti A, Modlin IM, Scott AM, Schöder H.

J Nucl Med. 2019 Dec;60(12):1663-1664. doi: 10.2967/jnumed.119.232454. Epub 2019 Nov 15. No abstract available.

PMID:
31732675
2.

Cobimetinib-induced "dropped head syndrome" and subsequent disease management in an Erdheim-Chester patient.

King AC, Diamond EL, Orozco JS, Morse HR, Ouyang LL, Schöder H, Rampal RK.

Clin Case Rep. 2019 Sep 10;7(10):1989-1993. doi: 10.1002/ccr3.2297. eCollection 2019 Oct.

3.

Correction to: 18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors.

Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, Mauguen A, Schöder H, Weber WA, Lassman AB, Blasberg R.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):4. doi: 10.1007/s00259-019-04514-1.

PMID:
31492997
4.

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K.

Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.

PMID:
31440799
5.

18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors.

Michaud L, Beattie BJ, Akhurst T, Dunphy M, Zanzonico P, Finn R, Mauguen A, Schöder H, Weber WA, Lassman AB, Blasberg R.

Eur J Nucl Med Mol Imaging. 2019 Aug 15. doi: 10.1007/s00259-019-04433-1. [Epub ahead of print] Erratum in: Eur J Nucl Med Mol Imaging. 2019 Sep 7;:.

PMID:
31418054
6.

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.

Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW.

Blood. 2019 Oct 10;134(15):1238-1246. doi: 10.1182/blood.2019000719.

PMID:
31331918
7.

Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma.

Mayerhoefer ME, Riedl CC, Kumar A, Gibbs P, Weber M, Tal I, Schilksy J, Schöder H.

Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2760-2769. doi: 10.1007/s00259-019-04420-6. Epub 2019 Jul 8.

PMID:
31286200
8.

MRI and PET/MRI in hematologic malignancies.

Mayerhoefer ME, Archibald SJ, Messiou C, Staudenherz A, Berzaczy D, Schöder H.

J Magn Reson Imaging. 2019 Jul 1. doi: 10.1002/jmri.26848. [Epub ahead of print] Review.

PMID:
31260155
9.

Task Group 174 Report: Utilization of [18 F]Fluorodeoxyglucose Positron Emission Tomography ([18 F]FDG-PET) in Radiation Therapy.

Das SK, McGurk R, Miften M, Mutic S, Bowsher J, Bayouth J, Erdi Y, Mawlawi O, Boellaard R, Bowen SR, Xing L, Bradley J, Schoder H, Yin FF, Sullivan DC, Kinahan P.

Med Phys. 2019 Oct;46(10):e706-e725. doi: 10.1002/mp.13676. Epub 2019 Sep 6.

PMID:
31230358
10.

Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.

Sherman EJ, Dunn LA, Schöder H, Ho AL, Baxi SS, Ghossein RA, Haque SS, Sima C, Tuttle RM, Pfister DG.

Cancer. 2019 Sep 1;125(17):2984-2990. doi: 10.1002/cncr.32046. Epub 2019 Jun 7.

PMID:
31174237
11.

Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction.

Krebs S, Ponomarev V, Slovin S, Schöder H.

J Nucl Med. 2019 Jul;60(7):879-881. doi: 10.2967/jnumed.119.227561. Epub 2019 May 3. No abstract available.

PMID:
31053682
12.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP.

J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.

PMID:
30939090
13.

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA.

JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096.

14.

An International Survey of PET/CT Clinical Reporting.

Zukotynski KA, Niederkohr RD, Greenspan BS, Prior JO, Schöder H, Seltzer MA, Rohren EM, Yoo DC.

J Nucl Med. 2019 Apr;60(4):478-479. doi: 10.2967/jnumed.118.223073. Epub 2019 Mar 15. No abstract available.

PMID:
30877176
15.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW.

Blood. 2019 Apr 18;133(16):1762-1765. doi: 10.1182/blood-2018-08-870915. Epub 2019 Feb 5.

PMID:
30723079
16.

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.

Mehta-Shah N, Ito K, Bantilan K, Moskowitz AJ, Sauter C, Horwitz SM, Schöder H.

Blood Adv. 2019 Jan 22;3(2):187-197. doi: 10.1182/bloodadvances.2018024075.

17.

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.

Lansigan F, Barak I, Pitcher B, Jung SH, Cheson BD, Czuczman M, Martin P, Hsi E, Schöder H, Smith S, Bartlett NL, Leonard JP, Blum KA.

Cancer Med. 2019 Jan;8(1):165-173. doi: 10.1002/cam4.1918. Epub 2018 Dec 21.

18.

Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy.

Ito K, Schöder H, Teng R, Humm JL, Ni A, Wolchok JD, Weber WA.

Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):930-939. doi: 10.1007/s00259-018-4211-0. Epub 2018 Nov 28.

PMID:
30488098
19.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
20.

18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.

Ito K, Teng R, Schöder H, Humm JL, Ni A, Michaud L, Nakajima R, Yamashita R, Wolchok JD, Weber WA.

J Nucl Med. 2019 Mar;60(3):335-341. doi: 10.2967/jnumed.118.213652. Epub 2018 Nov 9.

21.

Commentary from the Editors of the Continuing Education Section.

Schöder H, Strauss HW.

J Nucl Med. 2018 Aug;59(8):1183. No abstract available.

22.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL.

Blood. 2018 Sep 6;132(10):1013-1021. doi: 10.1182/blood-2018-01-827246. Epub 2018 Jul 26.

23.

11C-Choline Pharmacokinetics in Recurrent Prostate Cancer.

Grkovski M, Gharzeddine K, Sawan P, Schöder H, Michaud L, Weber WA, Humm JL.

J Nucl Med. 2018 Nov;59(11):1672-1678. doi: 10.2967/jnumed.118.210088. Epub 2018 Apr 6.

24.

Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma.

Qi S, Huang MY, Yang Y, Schöder H, Teckie S, Noy A, Chau K, Yahalom J.

Blood Adv. 2018 Mar 27;2(6):649-655. doi: 10.1182/bloodadvances.2017013698.

25.

Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management.

Sawan P, Rebeiz K, Schoder H, Batlevi C, Moskowitz A, Ulaner GA, Dunphy M, Mannelli L.

Medicine (Baltimore). 2017 Dec;96(51):e9411. doi: 10.1097/MD.0000000000009411.

26.

A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.

Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, Kumar A, Noy A, Palomba ML, Portlock CS, Straus DJ, Zelenetz AD, McCall SJ, Miller ST, Courtien AI, Younes A, Moskowitz CH.

Blood. 2018 Apr 19;131(16):1805-1808. doi: 10.1182/blood-2017-08-802561. Epub 2018 Jan 31.

27.

Response to the Letter to the Editor by CM den Bakker and DL van Der Peet.

Coit DG, Hernandez J, Schoder H, Goldman D.

Ann Surg. 2018 Dec;268(6):e79-e80. doi: 10.1097/SLA.0000000000002676. No abstract available.

PMID:
29334563
28.

Ectopic Undescended Parathyroid Adenoma-SPECT/CT Avoids False-Negative Interpretation on 99mTc-MIBI Dual-Phase Scintigraphy.

Mahajan S, Schoder H.

Clin Nucl Med. 2018 Mar;43(3):199-200. doi: 10.1097/RLU.0000000000001958.

PMID:
29293139
29.

Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features.

Crispin-Ortuzar M, Apte A, Grkovski M, Oh JH, Lee NY, Schöder H, Humm JL, Deasy JO.

Radiother Oncol. 2018 Apr;127(1):36-42. doi: 10.1016/j.radonc.2017.11.025. Epub 2017 Dec 19.

30.

Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage-Case Report.

Krebs S, Ganly I, Ghossein R, Yang J, Yahalom J, Schöder H.

Front Oncol. 2017 Nov 27;7:284. doi: 10.3389/fonc.2017.00284. eCollection 2017.

31.

Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.

Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, Larson SM.

JAMA Oncol. 2018 Feb 1;4(2):217-224. doi: 10.1001/jamaoncol.2017.3588.

32.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH.

Blood. 2017 Nov 16;130(20):2196-2203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5.

33.

Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma.

Hernandez JM, Beylergil V, Goldman DA, van Beek E, Gonen M, Tang L, Downey R, Rizk N, Shah M, Strong V, Janjigian Y, Schöder H, Coit DG.

Ann Surg. 2018 May;267(5):898-904. doi: 10.1097/SLA.0000000000002306.

34.

Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer.

O'Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schöder H, Larson SM, Beylergil V, Ruan S, Lyashchenko SK, Zanzonico PB, Weber WA, Carrasquillo JA, Janjigian YY.

J Nucl Med. 2018 Jan;59(1):161-166. doi: 10.2967/jnumed.117.194555. Epub 2017 Jun 21.

35.

Positron-emission tomography enhancement after vocal fold injection medialization.

Grant N, Wong RJ, Kraus DH, Schoder H, Branski RC.

Ear Nose Throat J. 2017 Jun;96(6):218-224.

PMID:
28636732
36.

Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics.

Folkert MR, Setton J, Apte AP, Grkovski M, Young RJ, Schöder H, Thorstad WL, Lee NY, Deasy JO, Oh JH.

Phys Med Biol. 2017 Jul 7;62(13):5327-5343. doi: 10.1088/1361-6560/aa73cc. Epub 2017 Jun 12.

37.

Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer.

Grkovski M, Lee NY, Schöder H, Carlin SD, Beattie BJ, Riaz N, Leeman JE, O'Donoghue JA, Humm JL.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1682-1691. doi: 10.1007/s00259-017-3720-6. Epub 2017 May 24.

38.

Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer.

Shukla-Dave A, Wassberg C, Pucar D, Schöder H, Goldman DA, Mazaheri Y, Reuter VE, Eastham J, Scardino PT, Hricak H.

World J Radiol. 2017 Mar 28;9(3):134-142. doi: 10.4329/wjr.v9.i3.134.

39.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

40.

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.

PMID:
28283702
41.

Pharmacokinetic Analysis of Dynamic 18F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer.

Schwartz J, Grkovski M, Rimner A, Schöder H, Zanzonico PB, Carlin SD, Staton KD, Humm JL, Nehmeh SA.

J Nucl Med. 2017 Jun;58(6):911-919. doi: 10.2967/jnumed.116.180422. Epub 2017 Feb 23.

42.

Multiparametric Imaging of Tumor Hypoxia and Perfusion with 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer.

Grkovski M, Schöder H, Lee NY, Carlin SD, Beattie BJ, Riaz N, Leeman JE, O'Donoghue JA, Humm JL.

J Nucl Med. 2017 Jul;58(7):1072-1080. doi: 10.2967/jnumed.116.188649. Epub 2017 Feb 9.

43.

Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211.

Hatt M, Lee JA, Schmidtlein CR, Naqa IE, Caldwell C, De Bernardi E, Lu W, Das S, Geets X, Gregoire V, Jeraj R, MacManus MP, Mawlawi OR, Nestle U, Pugachev AB, Schöder H, Shepherd T, Spezi E, Visvikis D, Zaidi H, Kirov AS.

Med Phys. 2017 Jun;44(6):e1-e42. doi: 10.1002/mp.12124. Epub 2017 May 18.

44.

Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement.

Nicolau C, Sala E, Kumar A, Goldman DA, Schoder H, Hricak H, Vargas HA.

AJR Am J Roentgenol. 2017 Apr;208(4):849-853. doi: 10.2214/AJR.16.17133. Epub 2017 Jan 17.

45.

Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer.

Grkovski M, Schwartz J, Rimner A, Schöder H, Carlin SD, Zanzonico PB, Humm JL, Nehmeh SA.

EJNMMI Res. 2016 Dec;6(1):79. Epub 2016 Nov 7.

46.

Metabolic Tumor Volume in Lymphoma: Hype or Hope?

Schöder H, Moskowitz C.

J Clin Oncol. 2016 Oct 20;34(30):3591-3594. doi: 10.1200/JCO.2016.69.3747. No abstract available.

47.

Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience.

Won E, Shah MA, Schöder H, Strong VE, Coit DG, Brennan MF, Kelsen DP, Janjigian YY, Tang LH, Capanu M, Rizk NP, Allen PJ, Bains MS, Ilson DH.

J Gastrointest Oncol. 2016 Aug;7(4):506-14. doi: 10.21037/jgo.2016.06.01.

48.

Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.

Lee N, Schoder H, Beattie B, Lanning R, Riaz N, McBride S, Katabi N, Li D, Yarusi B, Chan S, Mitrani L, Zhang Z, Pfister DG, Sherman E, Baxi S, Boyle J, Morris LG, Ganly I, Wong R, Humm J.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):9-17. doi: 10.1016/j.ijrobp.2016.04.027. Epub 2016 May 7.

49.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH.

Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood-2016-03-703470. Epub 2016 Jul 25.

50.

Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates.

Quinn B, Dauer Z, Pandit-Taskar N, Schoder H, Dauer LT.

BMC Med Imaging. 2016 Jun 18;16(1):41. doi: 10.1186/s12880-016-0143-y.

Supplemental Content

Loading ...
Support Center